OBJECTIVES: Survival in melanoma has been increasing and the most recent interest is to observe the population-level impact of novel targeted therapies and immunotherapy. We analysed survival in melanoma from Denmark (DK), Finland (FI), Norway (NO) and Sweden (SE) over a 50-years period (1971-2020). METHODS: Relative 1-5/1- and 5-year survival data were obtained from the NORDCAN database for the years 1971-2020. We estimated annual changes in survival rates and determined significant breaking points for trends. RESULTS: Survival in melanoma has reached the point where 1-year survival is approaching 100% (men 97.5-98.6%, women 98.4-99.3%, depending on the country) and 5-year survival is 93% for men (91.5-95.2%) and 96% for women (95.3-97.2%). The highest survival figures were for DK. Significant increases in both 1- and 5-year survival were observed in most countries even towards the end of the follow-up (from 2006 to 2010-2011-2015 and further to 2016-2020). CONCLUSIONS: The main increase in melanoma survival took place up to year 1990, which was probably largely achieved through successful population campaigns for sun protection and programmes for early detection of lesions. Survival increased again after year 2000 up to the last period 2016-2020. This late development coincided with the introduction of targeted therapies using BRAF and BRAF/MEK inhibitors, and towards the end of the time period availability of checkpoint inhibitors. The success of melanoma treatment in DK was mostly likely due to the efficient use of modern therapies and to the centralised treatment for metastatic disease.

Biomedical Center Faculty of Medicine Charles University Pilsen 30605 Pilsen Czech Republic; Division of Cancer Epidemiology German Cancer Research Center Im Neuenheimer Feld 580 D 69120 Heidelberg Germany

Biomedical Center Faculty of Medicine Charles University Pilsen 30605 Pilsen Czech Republic; Institute of Pathological Physiology Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Cancer Gene Therapy Group Translational Immunology Research Program University of Helsinki Finland; Comprehensive Cancer Center Helsinki University Hospital Helsinki Finland

Cancer Gene Therapy Group Translational Immunology Research Program University of Helsinki Finland; Department of Urology Helsinki University Hospital Helsinki Finland

Hopp Children's Cancer Center Heidelberg Germany

Zobrazit více v PubMed

Di Carlo V., Stiller C.A., Eisemann N., Bordoni A., Matz M., Curado M.P., et al. Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1 578 482 adults diagnosed during 2000-2014 in 59 countries (CONCORD-3) Br J Dermatol. 2022;187(3):364–380. PubMed PMC

Hemminki J., Försti A., Hemminki A., Hemminki K. Survival trends in solid cancers in the Nordic countries through 50 years. Eur J Cancer. 2022;175:77–85. PubMed

Chattopadhyay S., Hemminki A., Försti A., Sundquist K., Sundquist J., Hemmiinki K. Familial risks and mortality in second primary cancers in melanoma. JNCI Cancer Spectr. 2019;2:pky068. PubMed PMC

Zheng G., Chattopadhyay S., Sundquist K., Sundquist J., Försti A., Hemminki A., et al. Association between tumor characteristics and second primary cancers with cutaneous melanoma survival: a nationwide cohort study. Pigment Cell Melanoma Res. 2020;33(4):625–632. PubMed

Wouters M.W., Michielin O., Bastiaannet E., Beishon M., Catalano O., Del Marmol V., et al. ECCO essential requirements for quality cancer care: Melanoma. Crit Rev Oncol Hematol. 2018;122:164–178. PubMed

Schadendorf D., van Akkooi A.C.J., Berking C., Griewank K.G., Gutzmer R., Hauschild A., et al. Melanoma. Lancet. 2018;392(10151):971–984. PubMed

Chen T., Fallah M., Forsti A., Kharazmi E., Sundquist K., Hemminki K. Risk of next melanoma in patients with familial and sporadic melanoma by number of previous melanomas. JAMA Dermatol. 2015;151(6):607–615. PubMed

Chen T., Hemminki K., Kharazmi E., Ji J., Sundquist K., Fallah M. Multiple primary (even in situ) melanomas in a patient pose significant risk to family members. Eur J Cancer. 2014;50(15):2659–2667. PubMed

Pomerantz H., Huang D., Weinstock M.A. Risk of subsequent melanoma after melanoma in situ and invasive melanoma: a population-based study from 1973 to 2011. J Am Acad Dermatol. 2015;72(5):794–800. PubMed

Utjes D., Lyth J., Lapins J., Eriksson H. Reduced disease-specific survival following a diagnosis of multiple primary cutaneous malignant melanomas-a nationwide, population-based study. Int J Cancer. 2017;141(11):2243–2252. PubMed

Read J., Wadt K.A., Hayward N.K. Melanoma genetics. J Med Genet. 2016;53(1):1–14. PubMed

Hemminki K., Srivastava A., Rachakonda S., Bandapalli O., Nagore E., Hemminki A., et al. Informing patients about their mutation tests: CDKN2A c.256G>A in melanoma as an example. Hered Cancer Clin Pract. 2020;18:15. PubMed PMC

Ellebaek E., Svane I.M., Schmidt H., Haslund C.A., Donia M., Hoejberg L., et al. The Danish metastatic melanoma database (DAMMED): a nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients. Cancer Epidemiol. 2021;73 PubMed

Bütepage G., Carlqvist P., Jacob J., Toft Hornemann A., Vertuani S. Overall survival of individuals with metastatic cancer in Sweden: a nationwide study. BMC Public Health. 2022;22(1):1913. PubMed PMC

Donia M., Ellebaek E., Øllegaard T.H., Duval L., Aaby J.B., Hoejberg L., et al. The real-world impact of modern treatments on the survival of patients with metastatic melanoma. Eur J Cancer. 2019;108:25–32. PubMed

Long G.V., Flaherty K.T., Stroyakovskiy D., Gogas H., Levchenko E., de Braud F., et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28(7):1631–1639. PubMed PMC

Dummer R., Ascierto P.A., Nathan P., Robert C., Schadendorf D. Rationale for immune checkpoint inhibitors plus targeted therapy in metastatic melanoma: a review. JAMA Oncol. 2020;6(12):1957–1966. PubMed

Arheden A., Skalenius J., Bjursten S., Stierner U., Ny L., Levin M., et al. Real-world data on PD-1 inhibitor therapy in metastatic melanoma. Acta Oncol. 2019;58(7):962–966. PubMed

Krakowski I., Bottai M., Häbel H., Masucci G., Girnita A., Smedby K.E., et al. Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting. J Eur Acad Dermatol Venereol. 2021;35(1):105–115. PubMed

Karhapää H., Mäkelä S., Laurén H., Jaakkola M., Schalin-Jäntti C., Hernberg M. Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma. Endocr Connect. 2022;11:2. PubMed PMC

Carlino M.S., Larkin J., Long G.V. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002–1014. PubMed

Steininger J., Gellrich F.F., Schulz A., Westphal D., Beissert S., Meier F. Systemic therapy of metastatic melanoma: on the road to cure. Cancers. 2021;13:6. PubMed PMC

Engholm G., Ferlay J., Christensen N., Bray F., Gjerstorff M.L., Klint A., et al. NORDCAN--a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49(5):725–736. PubMed

Pukkala E., Engholm G., Hojsgaard Schmidt L.K., Storm H., Khan S., Lambe M., et al. Nordic cancer registries - an overview of their procedures and data comparability. Acta Oncol. 2018;57:440–455. PubMed

Larønningen S., Ferlay J., Beydogan H., Bray F., Engholm G., Ervik M., et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries. Association of the Nordic Cancer Registries. Cancer Registry of Norway; 2022.

Lundberg F.E., Andersson T.M., Lambe M., Engholm G., Mørch L.S., Johannesen T.B., et al. Trends in cancer survival in the Nordic countries 1990-2016: the NORDCAN survival studies. Acta Oncol. 2020;59(11):1266–1274. PubMed

Tichanek F., Försti A., Liska V., Hemminki A., Hemminki K. Survival in colon, rectal and small intestinal cancers in the nordic countries through a half century. Cancers. 2023;15:3. PubMed PMC

Månsson-Brahme E., Johansson H., Larsson O., Rutqvist L.E., Ringborg U. Trends in incidence of cutaneous malignant melanoma in a Swedish population 1976-1994. Acta Oncol. 2002;41(2):138–146. PubMed

Ringborg U., Lagerlof B., Broberg M., Mansson-Brahme E., Platz A., Thorn M. Early detection and prevention of cutaneous malignant melanoma: emphasis on Swedish activities. Med Oncol Tumor Pharmacother. 1991;8(3):183–187. PubMed

Greinert R., de Vries E., Erdmann F., Espina C., Auvinen A., Kesminiene A., et al. European Code against Cancer 4th Edition: Ultraviolet radiation and cancer. Cancer Epidemiol. 2015;39(Suppl 1):S75–S83. PubMed

Bay C., Kejs A.M., Storm H.H., Engholm G. Incidence and survival in patients with cutaneous melanoma by morphology, anatomical site and TNM stage: a Danish Population-based Register Study 1989-2011. Cancer Epidemiol. 2015;39(1):1–7. PubMed

Forsea A.M. Melanoma epidemiology and early detection in Europe: diversity and disparities. Dermatol Pract Concept. 2020;10(3) PubMed PMC

Eriksson H., Nielsen K., Vassilaki I., Lapins J., Mikiver R., Lyth J., et al. Trend shifts in age-specific incidence for in situ and invasive cutaneous melanoma in Sweden. Cancers. 2021;13:11. PubMed PMC

Riihimäki M., Thomsen H., Sundquist K., Sundquist J., Hemminki K. Clinical landscape of cancer metastases. Cancer Med. 2018;7(11):5534–5542. PubMed PMC

Mervic L. Time course and pattern of metastasis of cutaneous melanoma differ between men and women. PLoS One. 2012;7(3) PubMed PMC

Tas F., Erturk K. Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors. Melanoma Res. 2017;27(2):134–139. PubMed

Allemani C., Matsuda T., Di Carlo V., Harewood R., Matz M., Nikšić M., et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075. PubMed PMC